Compare VVX & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVX | IMNM |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2014 | 2020 |
| Metric | VVX | IMNM |
|---|---|---|
| Price | $65.72 | $20.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $62.60 | $31.44 |
| AVG Volume (30 Days) | 397.9K | ★ 3.4M |
| Earning Date | 02-23-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 791.53 | N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $4,419,142,000.00 | $9,679,000.00 |
| Revenue This Year | $4.53 | N/A |
| Revenue Next Year | $5.14 | $11.53 |
| P/E Ratio | $25.94 | ★ N/A |
| Revenue Growth | ★ 5.10 | N/A |
| 52 Week Low | $41.08 | $5.15 |
| 52 Week High | $65.50 | $25.30 |
| Indicator | VVX | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 74.68 | 48.09 |
| Support Level | $54.09 | $19.60 |
| Resistance Level | $56.38 | $22.01 |
| Average True Range (ATR) | 1.87 | 1.12 |
| MACD | 1.05 | -0.26 |
| Stochastic Oscillator | 91.12 | 22.51 |
V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.